INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $312,540 | -17.7% | 6,000 | 0.0% | 0.04% | -19.2% |
| Q2 2023 | $379,920 | -12.3% | 6,000 | -25.0% | 0.05% | -17.5% |
| Q1 2023 | $433,200 | -22.0% | 8,000 | -23.8% | 0.06% | -28.4% |
| Q4 2022 | $555,660 | +13.6% | 10,500 | 0.0% | 0.09% | +8.6% |
| Q3 2022 | $489,000 | -18.4% | 10,500 | 0.0% | 0.08% | -13.8% |
| Q2 2022 | $599,000 | -6.7% | 10,500 | 0.0% | 0.09% | +19.0% |
| Q1 2022 | $642,000 | -1.8% | 10,500 | -16.0% | 0.08% | +2.6% |
| Q4 2021 | $654,000 | +40.3% | 12,500 | 0.0% | 0.08% | +20.3% |
| Q3 2021 | $466,000 | -8.6% | 12,500 | 0.0% | 0.06% | -8.6% |
| Q2 2021 | $510,000 | +20.3% | 12,500 | 0.0% | 0.07% | +6.1% |
| Q1 2021 | $424,000 | +6.5% | 12,500 | 0.0% | 0.07% | 0.0% |
| Q4 2020 | $398,000 | +24.0% | 12,500 | 0.0% | 0.07% | +10.0% |
| Q3 2020 | $321,000 | -7.5% | 12,500 | -7.4% | 0.06% | -17.8% |
| Q2 2020 | $347,000 | +105.3% | 13,500 | +22.7% | 0.07% | +62.2% |
| Q1 2020 | $169,000 | -55.2% | 11,000 | 0.0% | 0.04% | -47.7% |
| Q4 2019 | $377,000 | +359.8% | 11,000 | 0.0% | 0.09% | +330.0% |
| Q3 2019 | $82,000 | -36.9% | 11,000 | +10.0% | 0.02% | -42.9% |
| Q2 2019 | $130,000 | +6.6% | 10,000 | 0.0% | 0.04% | +6.1% |
| Q1 2019 | $122,000 | +7.0% | 10,000 | 0.0% | 0.03% | -5.7% |
| Q4 2018 | $114,000 | -47.5% | 10,000 | 0.0% | 0.04% | -47.8% |
| Q3 2018 | $217,000 | +22.6% | 10,000 | 0.0% | 0.07% | +9.8% |
| Q2 2018 | $177,000 | -16.1% | 10,000 | 0.0% | 0.06% | -16.4% |
| Q1 2018 | $211,000 | +45.5% | 10,000 | 0.0% | 0.07% | +46.0% |
| Q4 2017 | $145,000 | -8.2% | 10,000 | 0.0% | 0.05% | -16.7% |
| Q3 2017 | $158,000 | +154.8% | 10,000 | +100.0% | 0.06% | +130.8% |
| Q2 2017 | $62,000 | -23.5% | 5,000 | 0.0% | 0.03% | -27.8% |
| Q1 2017 | $81,000 | +8.0% | 5,000 | 0.0% | 0.04% | -5.3% |
| Q4 2016 | $75,000 | -1.3% | 5,000 | 0.0% | 0.04% | -2.6% |
| Q3 2016 | $76,000 | -60.8% | 5,000 | 0.0% | 0.04% | -62.9% |
| Q2 2016 | $194,000 | +39.6% | 5,000 | 0.0% | 0.10% | +29.6% |
| Q1 2016 | $139,000 | -13.7% | 5,000 | +66.7% | 0.08% | -14.7% |
| Q4 2015 | $161,000 | +34.2% | 3,000 | 0.0% | 0.10% | +25.0% |
| Q3 2015 | $120,000 | +275.0% | 3,000 | +200.0% | 0.08% | +300.0% |
| Q2 2015 | $32,000 | +33.3% | 1,000 | 0.0% | 0.02% | +26.7% |
| Q1 2015 | $24,000 | – | 1,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |